Lotensin
(Benazepril)ApprovedSmall molecule
Lotensin is one of 103 small molecule programs targeting Albuminuria. It is currently in Approved.
4
Indications
10
Total Trials
0
Active Trials
102
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
885 competitors in Type 2 Diabetes
#DrugCompanyPhaseTrials
1Lotensin
VValidus Pharmaceuticals
Approved
Byetta
AstraZenecaPreclinical
Cysteine Hydrochloride
NovartisPreclinical
Glargine
Eli LillyPreclinical
Inspra
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Aurlumyn
BBTG International Inc.
Preclinical
Pravachol
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Preclinical
Sulfonylureas
Eli LillyPreclinical
GLP-1
RRigshospitalet, Denmark
Preclinical
Blank Control
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Renal insufficiency3 trials
Type 2 Diabetes2 trials
Peritoneal Dialysis1 trial
Albuminuria1 trial
Low Dose Versus Aggressive Inhibition of the Renin-Angiotensin-Aldosterone (RAS) to Treat Microalbuminuria
Completed·—·N/A·NCT00907374·46 enrolled
Regulatory
FDA Approval Timeline[4]
Jun 25, 1991
LOTENSIN
NDA NDA019851
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Benazepril. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- VValidus Pharmaceuticals